<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="pmcid: 678725112677 doi: 10.1038/s41467-019-12677-6 : Article Oligomeric state of the" exact="ZIKV" post="E protein defines protective immune responses http://orcid.org/0000-0002-9249-2844MetzStefan W.swmetz@med.unc.edu1ThomasAshlie1BrackbillAlex2ForsbergJohn2MileyMichael J.2LopezCesar"/>
 <result pre="copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The current leading" exact="Zika" post="vaccine candidates in clinical testing are based on live"/>
 <result pre="virus platforms, which have safety issues, especially in pregnant women." exact="Zika" post="subunit vaccines, however, have shown poor performance in preclinical"/>
 <result pre="tested do not display critical quaternary structure epitopes present on" exact="Zika" post="E protein homodimers that cover the surface of the"/>
 <result pre="recombinant E protein homodimers that are recognized by strongly neutralizing" exact="Zika" post="specific monoclonal antibodies. In mice, the dimeric antigen stimulate"/>
 <result pre="are similar to epitopes recognized by human antibodies following natural" exact="Zika" post="virus infection. The monomer antigen stimulates low levels of"/>
 <result pre="low levels of E-domain III targeting neutralizing antibodies. In a" exact="Zika" post="challenge model, only E dimer antigen stimulates protective antibodies,"/>
 <result pre="surface when designing subunit vaccines. Many human antibodies that neutralize" exact="Zika" post="virus recognize quaternary epitopes on the envelope (E) protein."/>
 <result pre="protein. Here, Metz et al. engineer stable recombinant homodimers of" exact="Zika" post="virus E protein and show that it induces neutralizing"/>
 <result pre="in mice that recognize similar epitopes as human antibodies from" exact="Zika" post="infected people. Subject terms Antibodies Protein vaccines Viral infection"/>
 <result pre="infected people. Subject terms Antibodies Protein vaccines Viral infection Introduction" exact="Zika" post="virus (ZIKV) is an enveloped single stranded RNA virus"/>
 <result pre="by mosquito vectors. As a member of the flavivirus genus," exact="ZIKV" post="shares many structural features with other medically important flaviviruses"/>
 <result pre="protective human antibodies bind to these higher order protein structures1." exact="ZIKV" post="infection during pregnancy can result in neurodevelopmental defects (congenital"/>
 <result pre="ZIKV infection during pregnancy can result in neurodevelopmental defects (congenital" exact="Zika" post="syndrome). This has stimulated work on subunit vaccines, as"/>
 <result pre="of these antigens in preclinical studies2,7,8. Here, we investigate if" exact="ZIKV" post="rE dimers are better subunit vaccine antigens than monomers."/>
 <result pre="the dimer is recognized by strongly neutralizing mAbs isolated from" exact="ZIKV" post="patients and the dimer, not the monomer, stimulates strongly"/>
 <result pre="were similar to epitopes recognized by human antibodies following natural" exact="Zika" post="virus infection. These results highlight the importance of mimicking"/>
 <result pre="and are applicable to developing second generation subunit vaccines against" exact="Zika" post="as well as other medically important flaviviruses like dengue"/>
 <result pre="important flaviviruses like dengue and yellow fever. Results Expression of" exact="ZIKV" post="rE monomers and homodimers Here, to investigate if ZIKV"/>
 <result pre="of ZIKV rE monomers and homodimers Here, to investigate if" exact="ZIKV" post="rE dimers are better subunit vaccine antigens than monomers,"/>
 <result pre="dimers are better subunit vaccine antigens than monomers, we expressed" exact="ZIKV" post="rE variants (aa1–402) that are monomers (rEM) or stable"/>
 <result pre="or stable dimers (rED) under physiological conditions. We generated stable" exact="ZIKV" post="rED proteins as previously described for DENV E protein"/>
 <result pre="We generated stable ZIKV rED proteins as previously described for" exact="DENV" post="E protein by introducing a disulfide bridge (A264C) in"/>
 <result pre="mAbs C8 and C10 (Fig. 1c). Fig. 1 Expression pf" exact="ZIKV" post="rE monomers and rE homodimers. a The soluble ZIKV"/>
 <result pre="pf ZIKV rE monomers and rE homodimers. a The soluble" exact="ZIKV" post="rE-monomer (rEM, aa1–404) was expressed and purified from mammalian"/>
 <result pre="was expressed and purified from mammalian cells. The soluble stable" exact="ZIKV" post="rE-homodimer (rED) was generated by an A264C substitution, resulting"/>
 <result pre="weights of ~49 kDa (monomer) and ~98 kDa (dimer). c Binding of" exact="ZIKV" post="specific (A9E, G9E, and ZKA-230) and flavivirus cross-reactive (4G2,"/>
 <result pre="and flavivirus cross-reactive (4G2, 1M7, C8, and C10) mAbs to" exact="ZIKV" post="rEM and rED was analyzed. Binding of mAbs that"/>
 <result pre="deviation. Source data are provided as a Source Data file" exact="ZIKV" post="rED, but not rEM, induces neutralizing antibodies After confirming"/>
 <result pre="in the absence of alumn, these antibodies failed to neutralize" exact="ZIKV" post="(Fig. 2d). In contrast, non-adjuvanted rED elicited ZIKV-neutralizing antibodies"/>
 <result pre="potently neutralizing compared with the rEM stimulated antibodies. Fig. 2" exact="ZIKV" post="rED induces neutralizing antibody responses. a Mice were primed"/>
 <result pre="neutralizing antibody responses. a Mice were primed with 5 µg of" exact="ZIKV" post="rEM or rED (+/−alum) and boosted with similar doses"/>
 <result pre="deviation. Source data are provided as a Source Data file" exact="ZIKV" post="rED stimulates antibodies that target complex epitopes We next"/>
 <result pre="by rEM and rED antigens recognized different epitopes on the" exact="ZIKV" post="E protein. Many flavivirus type-specific antibodies recognize relatively simple"/>
 <result pre="rED+alum). The antibody binding patterns were also reflected in the" exact="ZIKV" post="neutralization assays. The majority of neutralizing antibodies in the"/>
 <result pre="that target epitopes distinct from simple EDIII epitopes. Fig. 3" exact="ZIKV" post="rED stimulates antibodies that target complex epitopes on the"/>
 <result pre="Method for depleting EDIII-binding antibodies from mouse immune sera. Recombinant" exact="ZIKV" post="E-domain III (EDIII, His-tagged) was coupled to nickel beadsi"/>
 <result pre="(A9E and G9E) from a person who was infected with" exact="ZIKV" post="in 201623. These antibodies map to complex epitopes on"/>
 <result pre="epitopes on domain I (A9E) and domain II (G9E) of" exact="ZIKV" post="E protein23. Moreover, antibody blockade assays using these mAbs"/>
 <result pre="mAbs also are targeted by antibodies in immune serum from" exact="Zika" post="patients but not dengue patients23. We used a blockade"/>
 <result pre="binds to a E dimer-dependent epitope that is conserved between" exact="DENV" post="and ZIKV. Sera from mice immunized with rEM did"/>
 <result pre="not block binding of A9E, G9E, and C10 mAbs to" exact="ZIKV" post="(Fig. 3d). In contrast, sera from mice immunized with"/>
 <result pre="ZIKV. These results demonstrate that the rED antigen and natural" exact="ZIKV" post="infections stimulate antibodies that target similar complex epitopes on"/>
 <result pre="antibodies and directs the antibody response to simple epitopes on" exact="ZIKV" post="EDIII. ZIKV rED induces protective antibodies in mice Next,"/>
 <result pre="directs the antibody response to simple epitopes on ZIKV EDIII." exact="ZIKV" post="rED induces protective antibodies in mice Next, we investigated"/>
 <result pre="vaccinated with rEM+alum and rED+alum could protect mice from lethal" exact="ZIKV" post="challenge. We immunized wild-type mice as previously described (Fig."/>
 <result pre="to ZIKV. Ifnar1−/− mice were challenged with 1000 FFU of" exact="ZIKV" post="H/PF/2013, 1 day post serum transfer. Mice were monitored"/>
 <result pre="post serum transfer. Mice were monitored for weight loss and" exact="ZIKV" post="induced disease, and mice were bled at days 0"/>
 <result pre="G9E was used as a positive control for protection against" exact="ZIKV" post="infection23. Mice that received G9E or serum from rED+alum"/>
 <result pre="against replicating virus in these animals (Fig. 4c). Fig. 4" exact="ZIKV" post="rED induce protective antibodies in mice. a Wild-type mice"/>
 <result pre="Ifnar1−/− mice 24 h prior to challenge with 1000 FFU of" exact="ZIKV" post="by subcutaneous footpad inoculation (n = 5 for rEM and rED"/>
 <result pre="Discussion The magnitude, sudden onset and severe clinical manifestations of" exact="ZIKV" post="epidemics highlight the need for safe and effective vaccines"/>
 <result pre="replication. It has been difficult to formulate tetravalent live attenuated" exact="DENV" post="vaccines that stimulate balanced and effective responses to each"/>
 <result pre="the surface of infectious virus particles. Here we demonstrate that" exact="ZIKV" post="rEM and rED subunit antigens induce antibody responses that"/>
 <result pre="induce antibody responses that differ in functionality and domain focus." exact="ZIKV" post="rE monomers stimulated an EDIII biased, poorly neutralizing IgG"/>
 <result pre="stimulated an EDIII biased, poorly neutralizing IgG response. In contrast," exact="ZIKV" post="rE dimers induced strongly neutralizing and protective antibodies that"/>
 <result pre="are needed to compare the immunogenicity, efficacy and safety of" exact="ZIKV" post="rE-dimer, inactivated virus and VLP vaccines. The strategy we"/>
 <result pre="virus and VLP vaccines. The strategy we describe here for" exact="ZIKV" post="E protein may also be applicable for developing subunit"/>
 <result pre="cells (ThermoFisher) were cultured in EXPI293 expression medium (Life Technologies)." exact="ZIKV" post="strain H/PF/2013 was grown in Vero cells and titered"/>
 <result pre="titered by focus-forming assay using flavivirus mAb E6026,27. Production of" exact="ZIKV" post="rE antigens The recombinant ZIKV E (H/PF/2013; aa1–404) monomers"/>
 <result pre="flavivirus mAb E6026,27. Production of ZIKV rE antigens The recombinant" exact="ZIKV" post="E (H/PF/2013; aa1–404) monomers (rEM) and stable E dimers"/>
 <result pre="samples were flash frozen and stored at −80 °C. Production of" exact="ZIKV" post="EDIII proteins ZIKA virus EDIII (H/PF/2013, aa302–403) was expressed"/>
 <result pre="and grown to and OD600 = 0.6 at 37 °C, shaking at 225 rpm." exact="ZIKV" post="EDIII expression was stimulated by adding 50 mM IPTG and"/>
 <result pre="Next, cells were pelleted and lysed by high pressure homogenization." exact="ZIKV" post="EDIII proteins were purified from the lysate by Ni2+-affinity"/>
 <result pre="acid, 50% methanol). Protein confirmations were analyzed by antigen-capture ELISA." exact="ZIKV" post="rEM and rED were captured on Ni2+-coated ELISA plates"/>
 <result pre="the Care and Use of Laboratory Animals). For evaluation of" exact="ZIKV" post="rE immunogenicity, mice were immunized subcutaneously in the flank"/>
 <result pre="of rE-induced antibodies, heat-inactivated immune sera were passively transferred to" exact="ZIKV" post="susceptible A129 mice. Serum samples (days 70 through 112)"/>
 <result pre="into A129 mice, via intraperitoneal route 1 day prior to" exact="ZIKV" post="challenge. The ZIKV-neutralizing mAb G9E23 was used as a"/>
 <result pre="positive control (200 µg/mouse, n = 3). Mice were challenged with 1000 FFU of" exact="ZIKV" post="(H/PF/2013) by subcutaneous footpad inoculation. Mice were weighed daily"/>
 <result pre="Mice losing 30% of their starting weight were humanely euthanized." exact="ZIKV" post="rE-induced antibody evaluation ZIKV-specific IgG responses were measured by"/>
 <result pre="evaluation ZIKV-specific IgG responses were measured by antigen-capture ELISA. Briefly," exact="ZIKV" post="was captured on 1M7 (2 ng per µl)-coated ELISA plates"/>
 <result pre="and incubated for 45 min at 37 °C with the amount of" exact="ZIKV" post="previously determined to infect ~15% of the cells. Cells"/>
 <result pre="software. Depletion of EDIII-binding IgG from mouse serum Bacterially expressed" exact="ZIKV" post="EDIII proteins (C-terminal 6 × His-tag) were conjugated to Ni-NTA Magnetic"/>
 <result pre="for subsequent IgG ELISA and neutralization assays. The percentage of" exact="ZIKV" post="EDIII-binding antibodies was calculated by dividing the EDIII-depleted IgG"/>
 <result pre="IgG titers by the control-depleted IgG titers. The percentage of" exact="ZIKV" post="EDIII neutralizing antibodies was calculated by dividing the EDIII-depleted"/>
 <result pre="blocking, plates were washed in PBS + 0.2% Tween and incubated with" exact="ZIKV" post="H/PF/2013 for 1 h at 37 °C. The plates were washed"/>
 <result pre="and developed with AP-substrate and absorbance was measured at 405 nm." exact="ZIKV" post="RNA qRT-PCR analysis Viral RNA was isolated from 30 µl"/>
 <result pre="60 °C) × 40 cycles. RNA was isolated from a known quantity of" exact="ZIKV" post="H/PF/2013 to generate a standard curve. Reporting summary Further"/>
 <result pre="grant W81-XWH-18-2-0035 (PI A. de Silva) and the European Union" exact="Zika" post="Plan Research Consortium. Author contributions S.W.M. and A.T. performed"/>
 <result pre="majority of experiments. A.B., J.F., and M.J.M. expressed and purified" exact="ZIKV" post="monomer and dimer proteins. C.A.L., H.M.L., and S.T. performed"/>
 <result pre="dengue virus infectionsAdv. Exp. Med. Biol.20181062637610.1007/978-981-10-8727-1_529845525 2.LaroccaRAet al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 3.BlockOKet al.A tetravalent recombinant dengue domain"/>
 <result pre="allows stable dimerization of secretory and virus-associated E proteins of" exact="Dengue" post="and Zika viruses in mammalian cellsSci. Rep.2017796610.1038/s41598-017-01097-528424472 10.RouvinskiAet al.Covalently"/>
 <result pre="dimerization of secretory and virus-associated E proteins of Dengue and" exact="Zika" post="viruses in mammalian cellsSci. Rep.2017796610.1038/s41598-017-01097-528424472 10.RouvinskiAet al.Covalently linked dengue"/>
 <result pre="virus (DENV) type 2 envelope protein domain 3 type-specific and" exact="DENV" post="complex-reactive critical epitope residuesJ. Gen. Virol.20159628829310.1099/vir.0.070813-025351518 13.ZhouYet al.The mechanism"/>
 <result pre="epitope monoclonal antibodies isolated from dengue patients are protective against" exact="Zika" post="virusmBio201671123113110.1128/mBio.01123-16 16.FibriansahGet al.A potent anti-dengue human antibody preferentially recognizes"/>
 <result pre="Vaccines2010913714710.1586/erv.09.13920109025 20.QuPet al.Insect cell-produced recombinant protein subunit vaccines protect against" exact="Zika" post="virus infectionAntivir. Res.20181549710310.1016/j.antiviral.2018.04.01029665376 21.YangMDentMLaiHSunHChenQImmunization of Zika virus envelope protein"/>
 <result pre="subunit vaccines protect against Zika virus infectionAntivir. Res.20181549710310.1016/j.antiviral.2018.04.01029665376 21.YangMDentMLaiHSunHChenQImmunization of" exact="Zika" post="virus envelope protein domain III induces specific and neutralizing"/>
 <result pre="protein domain III induces specific and neutralizing immune responses against" exact="Zika" post="virusVaccine2017354287429410.1016/j.vaccine.2017.04.05228669618 22.FlipseJSmitJMThe complexity of a dengue vaccine: a review"/>
 <result pre="Dis.201593749376710.1371/journal.pntd.0003749 23.Collins, M. H. et al. Human antibody response to" exact="Zika" post="targets type-specific quaternary structure epitopes. JCI Insight410.1172/jci.insight.124588 (2019). 24.MartinJHermidaLDengue"/>
 <result pre="2013. Genome Announc.210.1128/genomeA.00500-14 (2014). 27.BrienJDLazearHMDiamondMSPropagation, quantification, detection, and storage of" exact="West Nile" post="virusCurr. Protoc. Microbiol.20133115D 13 1115D 13 18 28.MetzSWet al.In"/>
 <result pre="18 28.MetzSWet al.In vitro assembly and stabilization of dengue and" exact="Zika" post="virus envelope protein homo-dimersSci. Rep.20177452410.1038/s41598-017-04767-628674411 29.HenchalEAMcCownJMBurkeDSSeguinMCBrandtWEEpitopic analysis of antigenic"/>
</results>
